Ligand ID: AMH


Drugbank ID:
DB00302
(Tranexamic Acid)


Indication:
For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.

Get human targets for AMH in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'AMH' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5V3C_A_AMHA402_1
(QUEUINE
TRNA-RIBOSYLTRANSFER
ASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
GLN D 118
GLY A  78
GLY A  79
ALA A  39
VAL A  95
1.80A17.32
EDO  D 201 ( 4.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5V3C_A_AMHA402_1
(QUEUINE
TRNA-RIBOSYLTRANSFER
ASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
GLN A 118
GLY D  78
GLY D  79
ALA D  39
VAL D  95
1.78A17.32
EDO  D 201 ( 4.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5V3C_A_AMHA402_1
(QUEUINE
TRNA-RIBOSYLTRANSFER
ASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
GLN A 118
GLY D  78
GLY D  79
ALA D  39
VAL D  95
1.76A17.32
EDO  D 203 (-3.7A)
None
EDO  D 203 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5V3C_A_AMHA402_1
(QUEUINE
TRNA-RIBOSYLTRANSFER
ASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
GLN D 118
GLY A  78
GLY A  79
ALA A  39
VAL A  95
1.79A17.32
EDO  A 207 ( 4.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5V3C_A_AMHA402_1
(QUEUINE
TRNA-RIBOSYLTRANSFER
ASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
GLN C 118
GLY A  78
GLY A  79
ALA A  39
VAL A  95
1.79A17.32
EDO  A 204 (-4.1A)
None
EDO  A 204 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5V3C_A_AMHA402_1
(QUEUINE
TRNA-RIBOSYLTRANSFER
ASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
GLN A 118
GLY C  78
GLY C  79
ALA C  39
VAL C  95
1.77A17.32
EDO  A 202 (-4.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1CEB_A_AMHA90_1
(PLASMINOGEN)		7btf NSP12
(SARS-CoV-2)		4 / 7
ARG A  55
ASP A  67
TYR A 122
ARG A  33
1.68A6.71
None